These results display a remarkable overlap with expression data from TCGA-PRAD, which shows a major upregulation of these EMT markers in “High PKCα” human prostate adenocarcinomas relative to the “Low-PKCα” patient group (Fig. 7C, right). This evidence concerns the gene PRKCA and prostate adenocarcinoma.